E. Letang - Ifakara Hlth Inst | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 29 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Real-world effectiveness of Dolutegravir plus Lamivudine (DTG+3TC) in treatment-naive people with HIV-1 (PWH) and low CD4+cell count or high viral load at baseline: A systematic literature review

E. Letang,T. J. Barber,C. Allavena,L. Hocqueloux, J. Casado,S. Di Giambenedetto, A. Cabello-Ubeda, A. d'Arminio Monforte,M. Kabra,J. Priest,A. Milinkovic, B. Jones

HIV MEDICINE (2023): 144-145

引用0浏览0引用

Systematic Literature Review of Real-World Experience with the 2-Drug Regimen Dolutegravir Plus Lamivudine (DTG+3TC) in People with HIV-1 (PWH) Aged ≥50 Years

E. Letang,S. Di Giambenedetto, A. d'Arminio Monforte, J. Casado, A. Cabello-Ubeda,L. Hocqueloux,C. Allavena,T. J. Barber,M. Kabra,J. Priest, A. Clark, B. Jones

HIV MEDICINE（2023）

引用0浏览0引用

Real-world experience with the two-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review

S. di Giambenedetto,S. Walmsley,B. Grinsztejn,M. Perez-Elias,N. Nwokolo,M. Kabra, B. Jones,E. Letang,M. Kisare

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

引用0浏览0引用

Lipid changes in real-world studies with the two-drug regimen dolutegravir and lamivudine (DTG+3TC) in people with HIV-1: a systematic literature review

E. Letang, J. Lo,A. Milinkovic,F. Maggiolo,S. di Giambenedetto,C. Mussini, I. Ungan Yoruk,C. Henegar,J. Priest,B. Young,M. Kabra, B. Jones

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

引用0浏览0引用

Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196

S. De Wit, F. Bonnet,O. Osiyemi,F. Bisshop,J. Olalla,J. Routy,C. Wyen,R. Moodley,K. Pappa, R. Wang,J. Oyee, P. Saggu,E. Letang,B. Wynne, B. Jones,K. Smith,M. Ait-Khaled

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

引用0浏览0引用

1285. Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir and Lamivudine in People with HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program

J. Slim,D. Ward,S. Schneider,M. Kabra,G. Verdier,B. Jones,E. Letang

Open forum infectious diseasesno. Supplement_2 (2022)

引用0浏览0引用

CD4+T-cell count below 200 cells/mm³ is associated with worse COVID-19 outcomes among people living with HIV regardless of virological suppression

D. K. Nomah,J. Reyes-Uruena,Y. Diaz,S. Moreno,J. Aceiton,A. Bruguera,R. M. Vivanco-Hidalgo,J. M. Llibre,P. Domingo,V. Falco,A. Imaz,C. Cortes,L. Force,E. Letang, I. Vilaro,J. Casabona,J. M. Miro

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2021）

引用1浏览0引用

ROUNDTABLE : post-acute sequelae of SARS-CoV-2 infection Chairs :

P Kumar, AE Clarke, C Jonsson-Oldenbüttel,S Di Giambenedetto, C Brites,L Hocqueloux, P-L Lu,J Oyee,A Oglesby,J Priest,E Blair, B Wynn, LA Gordon,E Letang,J van Wyk, LA Evitt

semanticscholar（2021）

引用0浏览0引用

HIV‐associated Neurocognitive Impairment in Stable People Living with HIV on ART in Rural Tanzania

M. Sanmarti,A. C. Meyer,A. Jaen,K. Robertson, N. Tan,H. Mapesi,L. Samson, R. Ndaki,M. Battegay,M. Tanner,M. Weisser,D. Dalmau,E. Letang

HIV medicine（2020）

引用5浏览0WOS引用

Clinical outcomes among HIV-infected Africans with advanced disease in Spain

A. Ramirez-Mena,A. Jaen,B. Alejos,I. Jarrin,S. Moreno,G. Wandeler,D. Dalmau,E. Letang

HIV MEDICINE（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn